Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Comparison of Tolerability Between 2-Weekly and 3-Weekly Docetaxel Regimen in Castration-resistant Prostate Cancer

YUSUKE SHIMURA, YUKIO SUGA, SHINGO ITAI, HIROAKI IWAMOTO, YUTA TAKEZAWA, HIROSHI YAEGASHI, KOUJI IZUMI, TSUTOMU SHIMADA, YOSHIMICHI SAI, RYO MATSUSHITA and ATSUSHI MIZOKAMI
Anticancer Research August 2020, 40 (8) 4291-4297; DOI: https://doi.org/10.21873/anticanres.14431
YUSUKE SHIMURA
1Department of Hospital Pharmacy, University Hospital, Kanazawa University, Kanazawa, Japan
2Department of Clinical Pharmacy and Healthcare Science, Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YUKIO SUGA
2Department of Clinical Pharmacy and Healthcare Science, Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: suga{at}staff.kanazawa-u.ac.jp
SHINGO ITAI
1Department of Hospital Pharmacy, University Hospital, Kanazawa University, Kanazawa, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROAKI IWAMOTO
3Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YUTA TAKEZAWA
3Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROSHI YAEGASHI
3Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KOUJI IZUMI
3Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TSUTOMU SHIMADA
1Department of Hospital Pharmacy, University Hospital, Kanazawa University, Kanazawa, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YOSHIMICHI SAI
1Department of Hospital Pharmacy, University Hospital, Kanazawa University, Kanazawa, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RYO MATSUSHITA
2Department of Clinical Pharmacy and Healthcare Science, Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ATSUSHI MIZOKAMI
3Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 40 no. 8 4291-4297
DOI 
https://doi.org/10.21873/anticanres.14431
PMID 
32727756

Published By 
International Institute of Anticancer Research
Print ISSN 
0250-7005
Online ISSN 
1791-7530
History 
  • Received June 2, 2020
  • Revision received June 20, 2020
  • Accepted June 24, 2020
  • Published online July 29, 2020.

Copyright & Usage 
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved

Author Information

  1. YUSUKE SHIMURA1,2,
  2. YUKIO SUGA2⇑,
  3. SHINGO ITAI1,
  4. HIROAKI IWAMOTO3,
  5. YUTA TAKEZAWA3,
  6. HIROSHI YAEGASHI3,
  7. KOUJI IZUMI3,
  8. TSUTOMU SHIMADA1,
  9. YOSHIMICHI SAI1,
  10. RYO MATSUSHITA2 and
  11. ATSUSHI MIZOKAMI3
  1. 1Department of Hospital Pharmacy, University Hospital, Kanazawa University, Kanazawa, Japan
  2. 2Department of Clinical Pharmacy and Healthcare Science, Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan
  3. 3Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
  1. Correspondence to: Yukio Suga, Department of Clinical Pharmacy and Healthcare Science, Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Takara-machi 13-1, Kanazawa, Ishikawa 920-8641, Japan. Tel: +81 762672831, Fax: +81 762672831, e-mail: suga{at}staff.kanazawa-u.ac.jp
View Full Text

Statistics from Altmetric.com

Cited By...

  • 6 Citations
  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

PreviousNext
Back to top

In this issue

Anticancer Research
Vol. 40, Issue 8
August 2020
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Comparison of Tolerability Between 2-Weekly and 3-Weekly Docetaxel Regimen in Castration-resistant Prostate Cancer
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
2 + 3 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Comparison of Tolerability Between 2-Weekly and 3-Weekly Docetaxel Regimen in Castration-resistant Prostate Cancer
YUSUKE SHIMURA, YUKIO SUGA, SHINGO ITAI, HIROAKI IWAMOTO, YUTA TAKEZAWA, HIROSHI YAEGASHI, KOUJI IZUMI, TSUTOMU SHIMADA, YOSHIMICHI SAI, RYO MATSUSHITA, ATSUSHI MIZOKAMI
Anticancer Research Aug 2020, 40 (8) 4291-4297; DOI: 10.21873/anticanres.14431

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Comparison of Tolerability Between 2-Weekly and 3-Weekly Docetaxel Regimen in Castration-resistant Prostate Cancer
YUSUKE SHIMURA, YUKIO SUGA, SHINGO ITAI, HIROAKI IWAMOTO, YUTA TAKEZAWA, HIROSHI YAEGASHI, KOUJI IZUMI, TSUTOMU SHIMADA, YOSHIMICHI SAI, RYO MATSUSHITA, ATSUSHI MIZOKAMI
Anticancer Research Aug 2020, 40 (8) 4291-4297; DOI: 10.21873/anticanres.14431
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Conclusion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • Treatment Outcomes in Neuroendocrine Prostate Cancer
  • Google Scholar

More in this TOC Section

  • Potential of Inflammatory and Nutritional Markers and Clinicopathological Factors for Prognostic Prediction in Osteosarcoma
  • Diameter of IPDA Is Associated With Maintenance of Hepatic Arterial Blood Flow in DP-CAR
  • Postoperative Changes in Nutritional Status and their Impact on Post-recurrence Prognosis After Pancreatoduodenectomy in Patients With Biliary Tract Carcinoma: An Age-stratified Analysis
Show more Clinical Studies

Keywords

  • Leukopenia
  • febrile neutropenia
  • time to treatment failure
  • docetaxel
  • Prostate cancer
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire